Sign in
CompletedPhase 1

Neonatal Phase 1 Valacyclovir Study

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Atlanta, Birmingham, Charlotte, Columbus, Louisville, Milwaukee, Minneapolis, Omaha, Queens, Rochester, St Louis, and Syracuse, United StatesSee the 12 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
17 people enrolled
Started
7 Aug 2023
Ended
15 Jul 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Valacyclovir
Record updated
23 July 2026

Who can take part

Age
1 day to 2 days
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Signed informed consent from parent(s) or legal guardian(s)
  • Maternal history of genital HSV infection
  • Maternal receipt of oral acyclovir, valacyclovir, or famciclovir suppressive therapy for >/= 7 days prior to delivery
  • Gestational age >/= 38 weeks at birth
  • </= 2 days of age at study enrollment*
  • Weight at study enrollment >/= 2,000 grams; For purposes of this study, the calendar day of birth is Day of Life 0

Who cannot take part

  • Current receipt in the neonate of acyclovir, ganciclovir, famciclovir, or any investigational drugs
  • Evidence of neonatal HSV infection
  • Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry)
  • Evidence of sepsis
  • Known renal anomalies or dysfunction
  • Maternal genital lesions suspicious for HSV at the time of delivery

Where in United States

  • Emory University School of MedicineAtlanta, United States
  • Children's of Alabama Child Health Research Unit (CHRU)Birmingham, United States
  • Atrium Health ID Consultants & Infusion Care SpecialistsCharlotte, United States
  • Nationwide Children's HospitalColumbus, United States
  • University of Louisville School of Medicine - Norton Children's Hospital - Infectious DiseasesLouisville, United States
  • Medical College of WisconsinMilwaukee, United States
  • M Health Fairview Masonic Children's HospitalMinneapolis, United States
  • Children's NebraskaOmaha, United States
  • Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious DiseaseQueens, United States
  • University of Rochester Medical Center - Strong Memorial Hospital - Infectious DiseasesRochester, United States
  • Washington University in St. LouisSt Louis, United States
  • SUNY Upstate Medical University Hospital - PediatricsSyracuse, United States

About the trial

What the trial wants to find out

A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration. If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. The dose that these subjects will receive will be predicated upon the pharmacokinetic data from Cohort 1.

The 2 groups in the trial

  • Cohort 1Treatment being tested

    A cohort of neonates who are at risk of acquiring neonatal herpes simplex virus disease will receive 10 mg/kg of valacyclovir will be administered orally two times daily for 5 days. N=8

    Treatment: Valacyclovir

  • Cohort 2Treatment being tested

    If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. If the mean of observed acyclovir exposures of subjects in Cohort 1 are below 24,000 ngxhr/mL, AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose of 20 mg/kg administered two times daily for 5 days. Alternatively, if the mean of observed acyclovir exposures of subjects in Cohort 1 are above 48,000 ngxhr/mL AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose that has been linearly adjusted downward to target 36,000 ngxh/mL area-under-the-concentration-time curve from 0 to 12 hours (AUC12).

    Treatment: Valacyclovir

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Adaptive, Multiple Dose Pharmacokinetic and Safety Assessment of Valacyclovir in Infants at Risk of Acquiring Neonatal Herpes Simplex Virus Disease
Record updated
23 July 2026